277 related articles for article (PubMed ID: 26961539)
1. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
Ayalasomayajula S; Pan W; Han Y; Yang F; Langenickel T; Pal P; Zhou W; Yuan Y; Rajman I; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):309-318. PubMed ID: 27245340
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
[TBL] [Abstract][Full Text] [Related]
4. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
6. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
[TBL] [Abstract][Full Text] [Related]
7. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
Ayalasomayajula S; Langenickel TH; Chandra P; Wolfson ED; Albrecht D; Zhou W; Pal P; Rajman I; Sunkara G
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1012-1018. PubMed ID: 27719743
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Gan L; Jiang X; Mendonza A; Swan T; Reynolds C; Nguyen J; Pal P; Neelakantham S; Dahlke M; Langenickel T; Rajman I; Akahori M; Zhou W; Rebello S; Sunkara G
Clin Pharmacol Drug Dev; 2016 Jan; 5(1):27-39. PubMed ID: 27119576
[TBL] [Abstract][Full Text] [Related]
11. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
[TBL] [Abstract][Full Text] [Related]
12. Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide.
Ayalasomayajula S; Schuehly U; Pal P; Chen F; Zhou W; Sunkara G; Langenickel TH
Br J Clin Pharmacol; 2018 May; 84(5):926-936. PubMed ID: 29318651
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
14. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).
Ayalasomayajula S; Han Y; Langenickel T; Malcolm K; Zhou W; Hanna I; Alexander N; Natrillo A; Goswami B; Hinder M; Sunkara G
J Clin Pharm Ther; 2016 Aug; 41(4):424-31. PubMed ID: 27321165
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
Kulmatycki KM; Langenickel T; Ng WH; Pal P; Zhou W; Lin TH; Rajman I; Chandra P; Sunkara G
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):728-739. PubMed ID: 28737127
[TBL] [Abstract][Full Text] [Related]
16. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Ayalasomayajula S; Langenickel T; Pal P; Boggarapu S; Sunkara G
Clin Pharmacokinet; 2017 Dec; 56(12):1461-1478. PubMed ID: 28417439
[TBL] [Abstract][Full Text] [Related]
18. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
Flarakos J; Du Y; Bedman T; Al-Share Q; Jordaan P; Chandra P; Albrecht D; Wang L; Gu H; Einolf HJ; Huskey SE; Mangold JB
Xenobiotica; 2016 Nov; 46(11):986-1000. PubMed ID: 26931777
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
McCormack PL
Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
